 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 July 2001 | Volume 135 Issue 1 | Pages 27-31
Background: Tumor necrosis factor-
Objective: To treat sarcoidosis with infliximab, a chimeric human–murine anti–human TNF-
Design: Case report.
Setting: U.S. academic medical center.
Patient: A 72-year-old woman with sarcoidosis presenting with severe protein-losing enteropathy, hypoalbuminemia, and proximal myopathy who had not responded adequately to corticosteroid therapy and whose clinical course was further complicated by acute tubular necrosis and renal failure requiring long-term hemodialysis.
Intervention: Intravenous infusion of infliximab, 5 mg/kg of ideal body weight; infusion was repeated at 2 and 6 weeks.
Measurements: Clinical response of enteropathic and myopathic symptoms and serum albumin level.
Results: Enteropathic and myopathic symptoms resolved after infliximab therapy, and the serum albumin level also improved. However, the clinical course was complicated by the development of a hypercoagulable state associated with circulating anticardiolipin antibodies, which prompted discontinuation of infliximab therapy.
Conclusions: Infliximab therapy was successful in a patient with sarcoidosis. Tumor necrosis factor-
Author and Article Information
From Hospital for Special Surgery and New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York.
Acknowledgments: The authors thank Drs. Flavia A. Golden, Stephen A. Paget, and Lionel B. Ivashkiv for critical reading of the manuscript.
Requests for Single Reprints: Arthur M.F. Yee, MD, PhD, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021.
Current Author Addresses: Dr. Yee: Division of Rheumatic Diseases, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 East 70th Street, New York, NY 10021.
Dr. Pochapin: Division of Digestive Diseases, New York Presbyterian Hospital, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021.
Author Contributions: Conception and design: A.M.F. Yee.
Analysis and interpretation of the data: A.M.F. Yee, M.B. Pochapin.
Drafting of the article: A.M.F. Yee.
Critical revision of the article for important intellectual content: A.M.F. Yee, M.B. Pochapin.
Final approval of the article: A.M.F. Yee, M.B. Pochapin.
Provision of study materials or patients: A.M.F. Yee, M.B. Pochapin.
Administrative, technical, or logistic support: A.M.F. Yee.
Collection and assembly of data: A.M.F. Yee, M.B. Pochapin. BRIEF COMMUNICATION
Treatment of Complicated Sarcoidosis with Infliximab Anti–Tumor Necrosis Factor-
Therapy
(TNF-) may have an important role in the clinical exacerbation of sarcoidosis. monoclonal antibody. may be an important mediator of clinical disease in sarcoidosis and could be an attractive target for therapeutic intervention. However, infliximab may cause adverse effects associated with cytokine cascade manipulation.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui Interstitial lung disease guideline Thorax, September 1, 2008; 63(Suppl_5): v1 - v58. [Full Text] [PDF]
|
|
|
|
 |
|
 G H Louie, P Chitkara, and M M Ward Relapse of sarcoidosis upon treatment with etanercept Ann Rheum Dis, June 1, 2008; 67(6): 896 - 898. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Seyahi, V. Hamuryudan, G. Hatemi, M. Melikoglu, S. Celik, I. Fresko, S. Yurdakul, and H. Yazici Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behcet's syndrome Rheumatology, July 1, 2007; 46(7): 1213 - 1214. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Biester, C. Deuter, H. Michels, R. Haefner, J. Kuemmerle-Deschner, D. Doycheva, and M. Zierhut Adalimumab in the therapy of uveitis in childhood Br. J. Ophthalmol., March 1, 2007; 91(3): 319 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Grutters and J. M. M. van den Bosch Corticosteroid treatment in sarcoidosis. Eur. Respir. J., September 1, 2006; 28(3): 627 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tomlinson, K. Davies, D. A. Wright, and S. Holt Granulomatous interstitial nephritis treated with a tumour necrosis factor-{alpha} inhibitor Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2311 - 2314. [Full Text] [PDF]
|
|
|
|
|
|
M. Hammoudeh Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis Rheumatology, March 1, 2006; 45(3): 357 - 359. [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Heffernan and D. I. Smith Adalimumab for Treatment of Cutaneous Sarcoidosis Arch Dermatol, January 1, 2006; 142(1): 17 - 19. [Full Text] [PDF]
|
|
|
|
 |
|
 L. MANDEL, B. WOLINSKY, and E. C. CHALOM Treatment of refractory sarcoidal parotid gland swelling in a previously reported unresponsive case J Am Dent Assoc, September 1, 2005; 136(9): 1282 - 1285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Baughman, E. E. Lower, D. A. Bradley, L. A. Raymond, and A. Kaufman Etanercept for Refractory Ocular Sarcoidosis: Results of a Double-Blind Randomized Trial Chest, August 1, 2005; 128(2): 1062 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Doty, J. E. Mazur, and M. A. Judson Treatment of Sarcoidosis With Infliximab Chest, March 1, 2005; 127(3): 1064 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Grange, M. J. Nissen, K. Garambois, A. Dumolard, C. Duc, P. Gaudin, and R. Juvin Infliximab-induced cerebral thrombophlebitis Rheumatology, February 1, 2005; 44(2): 260 - 261. [Full Text] [PDF]
|
|
|
|
|
|
F. R. Pasternack, L. P. Fox, and D. E. Engler Silicone Granulomas Treated With Etanercept Arch Dermatol, January 1, 2005; 141(1): 13 - 15. [Full Text] [PDF]
|
|
|
|
|
|
E C Keystone The utility of tumour necrosis factor blockade in orphan diseases Ann Rheum Dis, November 1, 2004; 63(suppl_2): ii79 - ii83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Pritchard and K Nadarajah Tumour necrosis factor {alpha} inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients Ann Rheum Dis, March 1, 2004; 63(3): 318 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Roberts, D. S. Wilkes, R. A. Burgett, and K. S. Knox Refractory Sarcoidosis Responding to Infliximab Chest, November 1, 2003; 124(5): 2028 - 2031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Utz, A. H. Limper, S. Kalra, U. Specks, J. P. Scott, Z. Vuk-Pavlovic, and D. R. Schroeder Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis Chest, July 1, 2003; 124(1): 177 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Morcos, J.A. Pettersen, D.W. Zochodne, R.B. Bell, and M.D. Hill Refractory neurosarcoidosis responding to infliximab Neurology, April 8, 2003; 60(7): 1220 - 1221. [Full Text] [PDF]
|
|
|
|
 |
|
 R. N Serio Infliximab Treatment of Sarcoidosis Ann. Pharmacother., April 1, 2003; 37(4): 577 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Katz, M. K. Bruno, J. M. S. Winterkorn, and N. Nealon The Pathogenesis and Treatment of Optic Disc Swelling in Neurosarcoidosis: A Unique Therapeutic Response to Infliximab Arch Neurol, March 1, 2003; 60(3): 426 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.A. Pettersen, D.W. Zochodne, R.B. Bell, L. Martin, and M.D. Hill Refractory neurosarcoidosis responding to infliximab Neurology, November 26, 2002; 59(10): 1660 - 1660. [Full Text] [PDF]
|
|
|
|
 |
|
 R Singh, M D Conway, and W A Wilson Antiphospholipid syndrome in a patient with sarcoidosis: a case report Lupus, November 1, 2002; 11(11): 756 - 758. [Abstract] [PDF]
|
|
|
|
 |
|
 M. C. Cook Infliximab Therapy for Complicated Sarcoidosis Ann Intern Med, August 20, 2002; 137(4): 296 - 296. [Full Text] [PDF]
|
|
|
|
|
|
T. M. O'Connor, F. Shanahan, and C. P. Bredin Infliximab Therapy for Complicated Sarcoidosis Ann Intern Med, August 20, 2002; 137(4): 296 - 297. [Full Text] [PDF]
|
|
Article
